202 related articles for article (PubMed ID: 29187928)
1. Hormone-receptor expression status of epithelial ovarian cancer in Ibadan, South-western Nigeria.
Ajani MA; Salami A; Awolude OA; Oluwasola AO
Pan Afr Med J; 2017; 27():259. PubMed ID: 29187928
[TBL] [Abstract][Full Text] [Related]
2. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
[TBL] [Abstract][Full Text] [Related]
3. Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer.
Yoffou PH; Edjekouane L; Meunier L; Tremblay A; Provencher DM; Mes-Masson AM; Carmona E
PLoS One; 2011; 6(6):e20705. PubMed ID: 21695196
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria.
Ajani MA; Lawan A; Oke T; Khramtsova G; Nwanji I; Salami A; Awolude O; Ebili H; Onwukamuche ME; Sveen E; Yoshimatsu T; Olopade OI
Afr Health Sci; 2023 Sep; 23(3):236-244. PubMed ID: 38357171
[TBL] [Abstract][Full Text] [Related]
7. Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers.
Buchynska LG; Iurchenko NP; Grinkevych VM; Nesina IP; Chekhun SV; Svintsitsky VS
Exp Oncol; 2009 Mar; 31(1):48-51. PubMed ID: 19300417
[TBL] [Abstract][Full Text] [Related]
8. Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors.
Arias-Pulido H; Smith HO; Joste NE; Bocklage T; Qualls CR; Chavez A; Prossnitz ER; Verschraegen CF
Gynecol Oncol; 2009 Sep; 114(3):480-5. PubMed ID: 19560192
[TBL] [Abstract][Full Text] [Related]
9. Pattern of triple negative epithelial ovarian cancer in indigenous African women.
Ajani MA; Salami AA; Awolude OA; Oluwasola AO
F1000Res; 2016; 5():2415. PubMed ID: 27853516
[No Abstract] [Full Text] [Related]
10. The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer.
Chen S; Dai X; Gao Y; Shen F; Ding J; Chen Q
Sci Rep; 2017 Dec; 7(1):16922. PubMed ID: 29208958
[TBL] [Abstract][Full Text] [Related]
11. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.
Nodin B; Zendehrokh N; Sundström M; Jirström K
Diagn Pathol; 2013 Jun; 8():106. PubMed ID: 23800114
[TBL] [Abstract][Full Text] [Related]
13. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma.
Fujimura M; Hidaka T; Kataoka K; Yamakawa Y; Akada S; Teranishi A; Saito S
Am J Surg Pathol; 2001 May; 25(5):667-72. PubMed ID: 11342781
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor status predicts development of brain metastases in ovarian cancers.
Mittica G; Senetta R; Scotto G; Aglietta M; Maggiorotto F; Ghisoni E; Genta S; Boldorini R; Manini C; Morra I; Buosi R; Sapino A; Cassoni P; Valabrega G
Oncotarget; 2017 Jun; 8(25):41143-41153. PubMed ID: 28467804
[TBL] [Abstract][Full Text] [Related]
15. Estrogen and progesterone receptors in ovarian cancer.
Harding M; Cowan S; Hole D; Cassidy L; Kitchener H; Davis J; Leake R
Cancer; 1990 Feb; 65(3):486-91. PubMed ID: 2297640
[TBL] [Abstract][Full Text] [Related]
16. Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study.
Tangjitgamol S; Manusirivithaya S; Khunnarong J; Jesadapatarakul S; Tanwanich S
Int J Gynecol Cancer; 2009 May; 19(4):620-7. PubMed ID: 19509560
[TBL] [Abstract][Full Text] [Related]
17. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium.
Shabani N; Mylonas I; Jeschke U; Thaqi A; Kuhn C; Puchner T; Friese K
Anticancer Res; 2007; 27(4A):2027-33. PubMed ID: 17649817
[TBL] [Abstract][Full Text] [Related]
18. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.
Saied EM; El-Etreby NM
Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the contribution of immunologically-detectable HER2, steroid receptors and of the "triple-negative" tumor status to disease-free and overall survival of women with epithelial ovarian cancer.
de Toledo MC; Sarian LO; Sallum LF; Andrade LL; Vassallo J; de Paiva Silva GR; Pinto GA; Soares FA; Fonseca CD; Derchain SF
Acta Histochem; 2014 Apr; 116(3):440-7. PubMed ID: 24238473
[TBL] [Abstract][Full Text] [Related]
20. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS
Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
